More than 1,200 people took part in clinical studies (including patients with acute respiratory disease symptoms and complications and healthy volunteers). 805 study participants received the drug INGARON®. Recruitment took place during flu seasons when people are at high risk of being infected and get complications.
Therefore, based on virus identification data from these trials INGARON® is efficient against influenza types A and B, parainfluenza, coronavirus, adenovirus, and respiratory syncytial virus. In all studies INGARON® proved to reduce the duration of symptoms and hospitalization of patients, the severity and duration of catarrhal symptoms and symptoms of intoxication. Drug treatment was safe and well tolerated by all the participants with a minimal amount of adverse events.
In placebo-controlled blinded trials the incidence of acute respiratory viral infections, including the frequency of influenza virus detection, after preventive course of INGARON® decreases by 2 times. In cases of acute respiratory viral infections, the same positive effects are observed. The incidence of complicated forms of disease also drops by 2 times. Based on clinical studies and post-marketing research of the INGARON® use, it is included in clinical and methodological guidelines in Russia.